Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 392734, 5 pages
http://dx.doi.org/10.1100/2012/392734
Research Article

A Neutral Risk on the Development of New-Onset Diabetes Mellitus (NODM) in Taiwanese Patients with Dyslipidaemia Treated with Fibrates

1Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
2Department of Pharmacy, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
3Department of Health Service Administration, College of Public Health, China Medical University, Taichung 40402, Taiwan
4Division of Hepatogastroenterology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
5Department of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan

Received 7 May 2012; Accepted 2 July 2012

Academic Editors: E. Acquas, Z. Gao, and L. Virág

Copyright © 2012 Chien-Ying Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

There are no data on the incidence of new-onset diabetes mellitus (NODM ) in nondiabetic dyslipidaemia patients treated with fibrates. The aim of our study was to clarify these issues, to investigate the relationship between NODM and fibrate and whether the fibrates lead to increased risk for developing NODM. A retrospective cohort study was conducted by analyzing the Longitudinal Health Insurance Database (LHID 2005) of the National Health Insurance Research Database (NHIRD) from 2005 to 2010 to investigate all fibrate prescriptions for patients with dyslipidaemia. We estimated the hazard ratios (HRs) of NODM associated with fibrate use. We identified 145 NODM patients among 3,815 dyslipidaemic patients in the database for the study period. The risk estimates for NODM for users of fenofibrate (HR 1.30; 95% CI 0.82, 2.05) and gemfibrozil (HR 0.771; 95% CI 0.49, 1.22) were not associated with an increased risk of developing NODM ( 𝑃 > 0 . 0 5 ). Our results revealed that patients with dyslipidaemia who took fenofibrate and gemfibrozil had a neutral risk of NODM. The reasons may be associated with the fibrates have the properties that activate PPARα and in some cases also activated PPARγ, leading to showing a neutral risk of NODM.